Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis

Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines

“…22 The very high IgG value needed for protection against serotype 3 is rarely attained as a result of vaccination, which explains why the study concluded that PCV13 was ineffective against it. 23 In agreement with in vitro data showing that high IgG concentrations are needed to achieve complement deposition and kill this serotype is the high antibody concentrations required for protection against serotype 19F. 24 Interestingly, opsonophagocytic antibody titres of 1 in 8 or higher did not predict protection, thus suggesting that the validity of this marker should probably be revised and further reducing the importance of immune criteria when evaluating the potential protection provided by new PCVs.…”

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants

“…However, the pneumococcal vaccination schedule consisted of 4 doses per infant to yield the high immunogenicity. 8 When the additional cost of one dose of PCV was considered in the Maurer KA and colleagues' analysis, the ICERs of vaccination program with PCV-7, PCV-10, and PCV-13 against no vaccinations were higher than the threshold of 3 £ GDP of China, which indicates that the PCV vaccination program was not cost-effective in a Chinese context. Using the assumed cost of PCV-13 per course ($570), Mo X and colleagues have also found that PCV vaccinations for Chinese infants were not cost-effective, and they suggest that the price of the vaccine must be discounted and that financial support should be provided to poor families.…”

“…5 PCV-13 covers serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,18C, 19A, 19F and 23F, which cause most invasive pneumococcal diseases globally in Children. 6 Several large-scale clinical trials have demonstrated the clinically effective and safety profile of PCV-13 in infants and children, 7,8 demonstrating that vaccination programs could notably decrease the incidences of IPD, pneumonia, and otitis media. Furthermore, the direct effect can also extend the benefit to unvaccinated populations by decreasing the nasopharyngeal carriage of S. pneumonia in vaccinated children.…”

Bilan français des effets indésirables du vaccin Prévenar 13 ®

“…Dans notre étude, le profil des EI graves notifiés et leur incidence étaient assez similaires à ceux observés avec Prévenar 7 W [3]. Ceci est en accord avec les données publiées [10][11][12]. En effet, une méta-analyse [10] Après l'introduction du vaccin anti-pneumoccoccique, dans les années 2000 aux États-Unis, les infections invasives à pneumocoques ont diminué de façon importante chez les enfants vaccinés, avec un bénéfice s'étendant à l'entourage (effet troupeau).…”

“…Ceci est en accord avec les données publiées [10][11][12]. En effet, une méta-analyse [10] Après l'introduction du vaccin anti-pneumoccoccique, dans les années 2000 aux États-Unis, les infections invasives à pneumocoques ont diminué de façon importante chez les enfants vaccinés, avec un bénéfice s'étendant à l'entourage (effet troupeau). Cependant, la possibilité de modifications des sérotypes circulants induites par la vaccination nécessite d'être étroitement surveillée.…”